BR112014010664A2 - uso de um anticorpo anti-alfa-sinucleína para diagnosticar um nível elevado de alfa-sinucleína no cérebro - Google Patents
uso de um anticorpo anti-alfa-sinucleína para diagnosticar um nível elevado de alfa-sinucleína no cérebroInfo
- Publication number
- BR112014010664A2 BR112014010664A2 BR112014010664A BR112014010664A BR112014010664A2 BR 112014010664 A2 BR112014010664 A2 BR 112014010664A2 BR 112014010664 A BR112014010664 A BR 112014010664A BR 112014010664 A BR112014010664 A BR 112014010664A BR 112014010664 A2 BR112014010664 A2 BR 112014010664A2
- Authority
- BR
- Brazil
- Prior art keywords
- synuclein
- brain
- diagnose
- antibody
- high level
- Prior art date
Links
- 210000004556 brain Anatomy 0.000 title abstract 8
- 102000003802 alpha-Synuclein Human genes 0.000 title abstract 6
- 108090000185 alpha-Synuclein Proteins 0.000 title abstract 6
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 210000004369 blood Anatomy 0.000 abstract 2
- 239000008280 blood Substances 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 210000002381 plasma Anatomy 0.000 abstract 2
- 102000019355 Synuclein Human genes 0.000 abstract 1
- 108050006783 Synuclein Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/38—Pediatrics
- G01N2800/385—Congenital anomalies
- G01N2800/387—Down syndrome; Trisomy 18; Trisomy 13
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Neurosurgery (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Neurology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161554924P | 2011-11-02 | 2011-11-02 | |
| PCT/US2012/062430 WO2013066818A1 (en) | 2011-11-02 | 2012-10-29 | USE OF AN ANTI-α-SYNUCLEIN ANTIBODY TO DIAGNOSE AN ELEVATED LEVEL OF α-SYNUCLEIN IN THE BRAIN |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112014010664A2 true BR112014010664A2 (pt) | 2017-04-25 |
Family
ID=48192661
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014010664A BR112014010664A2 (pt) | 2011-11-02 | 2012-10-29 | uso de um anticorpo anti-alfa-sinucleína para diagnosticar um nível elevado de alfa-sinucleína no cérebro |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US20140295465A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2773957B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6263473B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102036938B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN107091931A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2012332814B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112014010664A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2854131C (cg-RX-API-DMAC7.html) |
| EA (1) | EA034213B1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL232373B (cg-RX-API-DMAC7.html) |
| MX (1) | MX356797B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2013066818A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA201403879B (cg-RX-API-DMAC7.html) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0923157B1 (pt) | 2008-12-19 | 2021-12-28 | University Of Zürich | Anticorpos anti-alfa-sinucleína e seus fragmentos, seus usos e método de preparação, composição compreendendo-os, bem como kit e métodos para o diagnóstico e monitoramento de uma doença sinucleinopática |
| PL2723379T3 (pl) | 2011-06-23 | 2019-05-31 | Biogen Int Neuroscience Gmbh | Cząsteczki wiążące przeciwko alfa-synukleinie |
| JP2017536102A (ja) | 2014-10-16 | 2017-12-07 | ジェネンテック， インコーポレイテッド | 抗アルファ−シヌクレイン抗体及び使用方法 |
| JP6273338B1 (ja) * | 2016-12-05 | 2018-01-31 | 磁量生技股▲ふん▼有限公司 | パーキンソン病からパーキンソン病認知症を特定する方法 |
| EP3567054A4 (en) * | 2017-01-06 | 2021-03-10 | ABL Bio Inc. | ANTI-ALPHA SYN ANTIBODIES AND USES THEREOF |
| CN110494445B (zh) | 2017-01-06 | 2023-10-20 | Abl生物公司 | 抗α-SYN抗体及其用途 |
| KR102573778B1 (ko) | 2017-02-17 | 2023-08-31 | 브리스톨-마이어스 스큅 컴퍼니 | 알파-시뉴클레인에 대한 항체 및 그의 용도 |
| WO2019117685A2 (ko) | 2017-12-14 | 2019-06-20 | 에이비엘바이오 주식회사 | 항-igf1r 항체 및 그 용도 |
| GB201803553D0 (en) | 2018-03-06 | 2018-04-18 | Univ Newcastle | Detection of pathological protein aggregation |
| WO2020009482A1 (ko) * | 2018-07-03 | 2020-01-09 | 에이비엘바이오 주식회사 | 항 알파-시누클레인 항체 및 그 용도 |
| EP3629021A1 (en) * | 2018-09-26 | 2020-04-01 | Euroimmun Medizinische Labordiagnostika AG | Diagnosis of a neuroautoimmune disease |
| KR102252879B1 (ko) * | 2019-11-15 | 2021-05-17 | 성균관대학교산학협력단 | 혈장 내 aimp2를 이용한 파킨슨 질환의 진단 방법, 이를 위한 조성물 및 이를 포함하는 키트 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4873192A (en) | 1987-02-17 | 1989-10-10 | The United States Of America As Represented By The Department Of Health And Human Services | Process for site specific mutagenesis without phenotypic selection |
| FR2686087A1 (fr) | 1992-01-13 | 1993-07-16 | Inst Nat Sante Rech Med | Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications. |
| WO1999050300A1 (en) * | 1998-03-30 | 1999-10-07 | The Trustees Of The University Of Pennsylvania | Method of identifying, diagnosing and treating synuclein positive neurodegenerative disorders |
| WO2002004482A1 (en) * | 2000-07-07 | 2002-01-17 | Panacea Pharmaceuticals, Inc. | Methods for preventing neural tissue damage and for the treatment of alpha-synuclein diseases |
| GB0203446D0 (en) * | 2002-02-14 | 2002-04-03 | Univ Lancaster | Detection and/or monitoring of synuclein-related diseases |
| CA2657953A1 (en) * | 2005-07-19 | 2007-01-25 | University Of Rochester | Alpha-synuclein antibodies and methods related thereto |
| HUE034512T2 (en) | 2007-01-05 | 2018-02-28 | Univ Zuerich | A method for providing disease-specific binding molecules and targets |
| CN101308144A (zh) * | 2007-05-16 | 2008-11-19 | 首都医科大学宣武医院 | 检测受试者体液内疾病相关蛋白聚合能力的方法 |
| LT2282758T (lt) * | 2008-04-29 | 2019-03-12 | Bioarctic Ab | Antikūnai ir vakcinos, skirti su alfa sinukleinu susijusių sutrikimų gydymo ir diagnostiniams metodams |
| BRPI0923157B1 (pt) * | 2008-12-19 | 2021-12-28 | University Of Zürich | Anticorpos anti-alfa-sinucleína e seus fragmentos, seus usos e método de preparação, composição compreendendo-os, bem como kit e métodos para o diagnóstico e monitoramento de uma doença sinucleinopática |
| CN101692092B (zh) * | 2009-09-24 | 2013-04-10 | 首都医科大学宣武医院 | 定量检测人血清中自体α-突触核蛋白抗体的方法 |
-
2012
- 2012-10-29 JP JP2014540007A patent/JP6263473B2/ja not_active Expired - Fee Related
- 2012-10-29 CA CA2854131A patent/CA2854131C/en active Active
- 2012-10-29 AU AU2012332814A patent/AU2012332814B2/en not_active Ceased
- 2012-10-29 BR BR112014010664A patent/BR112014010664A2/pt not_active Application Discontinuation
- 2012-10-29 CN CN201710252366.1A patent/CN107091931A/zh active Pending
- 2012-10-29 EA EA201490883A patent/EA034213B1/ru unknown
- 2012-10-29 KR KR1020147014713A patent/KR102036938B1/ko not_active Expired - Fee Related
- 2012-10-29 MX MX2014005378A patent/MX356797B/es active IP Right Grant
- 2012-10-29 CN CN201280065165.6A patent/CN104040342A/zh active Pending
- 2012-10-29 WO PCT/US2012/062430 patent/WO2013066818A1/en not_active Ceased
- 2012-10-29 US US14/355,743 patent/US20140295465A1/en not_active Abandoned
- 2012-10-29 EP EP12846452.6A patent/EP2773957B1/en active Active
-
2014
- 2014-04-30 IL IL232373A patent/IL232373B/en active IP Right Grant
- 2014-05-27 ZA ZA2014/03879A patent/ZA201403879B/en unknown
-
2017
- 2017-01-19 US US15/409,671 patent/US20180011112A1/en not_active Abandoned
-
2018
- 2018-05-16 US US15/981,691 patent/US20190094245A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2773957A1 (en) | 2014-09-10 |
| CA2854131A1 (en) | 2013-05-10 |
| IL232373A0 (en) | 2014-06-30 |
| NZ625217A (en) | 2016-07-29 |
| US20180011112A1 (en) | 2018-01-11 |
| JP6263473B2 (ja) | 2018-01-31 |
| AU2012332814B2 (en) | 2017-12-14 |
| MX356797B (es) | 2018-06-14 |
| MX2014005378A (es) | 2015-01-19 |
| ZA201403879B (en) | 2018-11-28 |
| CN107091931A (zh) | 2017-08-25 |
| EA201490883A1 (ru) | 2014-10-30 |
| IL232373B (en) | 2018-08-30 |
| AU2012332814A1 (en) | 2014-06-12 |
| US20190094245A1 (en) | 2019-03-28 |
| EP2773957B1 (en) | 2017-11-29 |
| WO2013066818A1 (en) | 2013-05-10 |
| CA2854131C (en) | 2020-07-07 |
| JP2014533357A (ja) | 2014-12-11 |
| US20140295465A1 (en) | 2014-10-02 |
| HK1201585A1 (en) | 2015-09-04 |
| EA034213B1 (ru) | 2020-01-17 |
| KR20140095074A (ko) | 2014-07-31 |
| CN104040342A (zh) | 2014-09-10 |
| KR102036938B1 (ko) | 2019-10-25 |
| EP2773957A4 (en) | 2015-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112014010664A2 (pt) | uso de um anticorpo anti-alfa-sinucleína para diagnosticar um nível elevado de alfa-sinucleína no cérebro | |
| BRPI1015088A2 (pt) | peptídeo antigênio ou um fragmento funcional deste, composição farmacêutica, métodos para o tratamento de uma doença ou distúrbio neurodegenerativos tal como tauopatia, para induzir uma resposta imune em um animal, para diagnosticar uma doença, distúrbio ou condição e uma predisposição a doença, distúrbio ou condição, para monitorar a doença residual mínima em um paciente e para prever a receptividade de um paciente, anticorpo, kit de teste, epítopo e linha celular. | |
| BR112012029281A2 (pt) | anticorpo trop-2 anti-humano tendo atividade anti-tumor in vivo | |
| BR112013033258A2 (pt) | moléculas de ligação de anti-alfa sinucleína | |
| BR112013023540A2 (pt) | anticorpo, kit e método para a determinação de peptídeos amilóides | |
| ECSP16060104A (es) | Anticuerpo pd-1, fragmento de unión al antígeno de este y uso médico de este | |
| BR112018074978A2 (pt) | anticorpos para alfa-sinucleína e usos dos mesmos | |
| BR112012007365A2 (pt) | proteínas de ligação à il-1 | |
| CY1116584T1 (el) | Ανθρωπινα αυτοαντισωματα αντι-αλφα-συνουκλεϊνης | |
| BR112014008382A2 (pt) | anticorpo especificamente ligando a epítope no domínio sema do c-met | |
| BRPI0914925A2 (pt) | peptídeo cíclico, uso de um peptídeo, métodos para produzir um peptídeo cíclico e para diagnosticar uma doença ou condição, e, anticorpo | |
| ECSP11011239A (es) | Proteínas ligadoras il-1 | |
| MX2015012437A (es) | Esteroides neuroactivos, composiciones, y usos de los mismos. | |
| CL2007000478A1 (es) | Anticuerpo humano o humanizado o fragmento funcional del mismo especifico para linfopoyetina estromal timica, tslp; polinucleotido que lo codifica; celula huesped que lo comprende; composicion farmaceutica que comprende al anticuerpo; y metodo para t | |
| BR112015021979A2 (pt) | Anticorpos humanos para grem1 | |
| WO2011142827A3 (en) | Diagnostic markers for neuropsychiatric disease | |
| UA115439C2 (uk) | Гуманізоване антитіло, яке розпізнає альфа-синуклеїн | |
| DOP2012000089A (es) | Anticuerpos monoclonales | |
| BR112015017403A2 (pt) | biomarcadores de terapia de combinação de anti-tnf e anti-il17 para doença inflamatória | |
| EA201290849A1 (ru) | Оптимизированные моноклональные антитела против ингибитора пути тканевого фактора (tfpi) | |
| WO2011100396A3 (en) | Serum clusterin levels in systemic amyloidosis featuring cardiomyopathy | |
| BR112015012708A2 (pt) | anticorpos para bmp-6 | |
| CL2011002416A1 (es) | Uso de un anticuerpo anti-il 17a y/o il-17f o fragmento que une antígeno del mismo que sirve en la preparación de un medicamento para el tratamiento de un trastorno de resistencia a insulina en un mamifero; kit. | |
| BR112013003279A2 (pt) | “métodos para tratar uma doença, método para neutralizar ou bloquear a atividade de il-1ß e/ou il-18, anticorpo, usos de um anticorpo e usos de um anticorpo monoclonal” | |
| BRPI0706575B8 (pt) | uso colágeno de tipo v ou um componente antigênico do mesmo, e, método para identificar um paciente em espera de transplante de pulmão para um risco aumentado de rejeição de tecido de órgão transplantado. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B25D | Requested change of name of applicant approved |
Owner name: BIOGEN INTERNATIONAL NEUROSCIENCE GMBH (CH) |
|
| B25G | Requested change of headquarter approved |
Owner name: BIOGEN INTERNATIONAL NEUROSCIENCE GMBH (CH) |
|
| B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] |
Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI. |
|
| B25G | Requested change of headquarter approved |
Owner name: BIOGEN INTERNATIONAL NEUROSCIENCE GMBH (CH) |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL |
|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |